Prise en charge thérapeutique des néoplasmes neuroendocrines métastatiques

comité tumeur neuro-endocrine de l'institut Gustave-Roussy

Prise en charge thérapeutique des néoplasmes neuroendocrines métastatiques

Translated title of the contribution: Therapeutic management of neuroendocrine neoplasms

comité tumeur neuro-endocrine de l'institut Gustave-Roussy

Research output: Contribution to journal › Article › peer-review

Abstract

Expert characterization is the basis of care. Prognostic heterogeneity is guiding therapeutic aggressiveness, early sequelae should be avoided. At the metastatic stage, therapy remains palliative. Standards have been established thanks to the recent phase III trial inplementations. Discovery of new therapeutic options is major goal for the future.

Translated title of the contribution	Therapeutic management of neuroendocrine neoplasms
Original language	French
Pages (from-to)	185-194
Number of pages	10
Journal	Correspondances en MHND
Volume	20
Issue number	7
State	Published - Sep 2016
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Carcinoma
Chemotherapy
Locoregional therapy
Metastasis
Neoplasm
Neuro endocrine
Targeted therapy
Tumor

Cite this

@article{a14bf1ae003e4f1a8e666c61f703bd62,

title = "Prise en charge th{\'e}rapeutique des n{\'e}oplasmes neuroendocrines m{\'e}tastatiques",

abstract = "Expert characterization is the basis of care. Prognostic heterogeneity is guiding therapeutic aggressiveness, early sequelae should be avoided. At the metastatic stage, therapy remains palliative. Standards have been established thanks to the recent phase III trial inplementations. Discovery of new therapeutic options is major goal for the future.",

keywords = "Carcinoma, Chemotherapy, Locoregional therapy, Metastasis, Neoplasm, Neuro endocrine, Targeted therapy, Tumor",

author = "\{comit{\'e} tumeur neuro-endocrine de l'institut Gustave-Roussy\} and {\'E}ric Baudin and Julien Hadoux and Lambros Tselikas and Leonor Benhaim and David Malka and Fr{\'e}d{\'e}ric Deschamps and Diane Goere and Caroline Caramella and Dominique Elias and S{\'e}gol{\`e}ne Hescot and Val{\'e}rie Boige and Pascal Burtin and Jean Lumbroso and Sophie Leboulleux and Marie Terroir and D{\'e}sir{\'e}e Deandreis and Scoazec, \{Jean Yves\} and Ghuzlan, \{Abir Al\} and Martin Schlumberger and Clarisse Dromain and Thierry Debaere and David Planchard and Amandine Berdelou and Michel Ducreux",

year = "2016",

month = sep,

language = "צרפתית",

volume = "20",

pages = "185--194",

journal = "Correspondances en MHND",

issn = "2100-9619",

publisher = "Edimark Sante",

number = "7",

}

TY - JOUR

T1 - Prise en charge thérapeutique des néoplasmes neuroendocrines métastatiques

AU - comité tumeur neuro-endocrine de l'institut Gustave-Roussy

AU - Baudin, Éric

AU - Hadoux, Julien

AU - Tselikas, Lambros

AU - Benhaim, Leonor

AU - Malka, David

AU - Deschamps, Frédéric

AU - Goere, Diane

AU - Caramella, Caroline

AU - Elias, Dominique

AU - Hescot, Ségolène

AU - Boige, Valérie

AU - Burtin, Pascal

AU - Lumbroso, Jean

AU - Leboulleux, Sophie

AU - Terroir, Marie

AU - Deandreis, Désirée

AU - Scoazec, Jean Yves

AU - Ghuzlan, Abir Al

AU - Schlumberger, Martin

AU - Dromain, Clarisse

AU - Debaere, Thierry

AU - Planchard, David

AU - Berdelou, Amandine

AU - Ducreux, Michel

PY - 2016/9

Y1 - 2016/9

N2 - Expert characterization is the basis of care. Prognostic heterogeneity is guiding therapeutic aggressiveness, early sequelae should be avoided. At the metastatic stage, therapy remains palliative. Standards have been established thanks to the recent phase III trial inplementations. Discovery of new therapeutic options is major goal for the future.

AB - Expert characterization is the basis of care. Prognostic heterogeneity is guiding therapeutic aggressiveness, early sequelae should be avoided. At the metastatic stage, therapy remains palliative. Standards have been established thanks to the recent phase III trial inplementations. Discovery of new therapeutic options is major goal for the future.

KW - Carcinoma

KW - Chemotherapy

KW - Locoregional therapy

KW - Metastasis

KW - Neoplasm

KW - Neuro endocrine

KW - Targeted therapy

KW - Tumor

UR - https://www.scopus.com/pages/publications/85012237157

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

AN - SCOPUS:85012237157

SN - 2100-9619

VL - 20

SP - 185

EP - 194

JO - Correspondances en MHND

JF - Correspondances en MHND

IS - 7

ER -

Prise en charge thérapeutique des néoplasmes neuroendocrines métastatiques

Abstract

UN SDGs

Keywords

Other files and links

Fingerprint

Cite this